ArticleExperimental and therapeutic medicine2020
Inhibition of miRNA-29a regulates intestinal barrier function in diarrhea-predominant irritable bowel syndrome by upregulating ZO-1 and CLDN1.
Article in Experimental and therapeutic medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 50 citations in OpenAlex.
- Association of IBS-associated E. coli strains with epithelial inflammatory responses and tight junction dysregulation in Caco-2 cells.BMC research notes · 2026Article
- Modulation of Inflammation and Gut Microbiota by aPharmaceutics · 2026Article
- Strain-Specific microRNA Reprogramming of Human Dendritic Cells by Probiotic and CommensalMicroorganisms · 2026Article
- Investigating the mechanisms of lactulose on gut health and uric acid metabolism in geese via transcriptomics.Scientific reports · 2025Article
- MicroRNA and Protein Biomarkers of Intestinal Permeability in the Assessment of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).International journal of molecular sciences · 2025Article
- Epithelial Barrier Function and Altered Cell Signaling Pathways in the Esophageal Epithelium of Achalasia Patients.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2025Article
- MicroRNAs as Key Modulators of Intestinal Barrier Function: Pattern Recognition Receptors, Epithelial Junctional Complexes, and Therapeutic Approaches.Digestive diseases and sciences · 2025Review
- miR-539-5p Regulates Irritable Bowel Syndrome Pathological Processes by Targeting KDM6A.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2025Article
- An optimised faecal microRNA sequencing pipeline reveals fibrosis in Trichuris muris infection.Nature communications · 2025Article
- The Role and the Regulation of NLRP3 Inflammasome in Irritable Bowel Syndrome: A Narrative Review.Microorganisms · 2025Review
- Insights into Microbiota-Host Crosstalk in the Intestinal Diseases Mediated by Extracellular Vesicles and Their Encapsulated MicroRNAs.International journal of molecular sciences · 2024Review
- Overexpression of miRNA29a gene inhibits proliferation and promotes apoptosis of jejunal epithelial cells in yak.Animal biotechnology · 2024Review
- Aberrant miR-29 is a predictive feature of severe phenotypes in pediatric Crohn's disease.JCI insight · 2024Article
- The role of gut microorganisms and metabolites in intracerebral hemorrhagic stroke: a comprehensive review.Frontiers in neuroscience · 2024Review
- Gut microbiota and irritable bowel syndrome: status and prospect.Frontiers in medicine · 2024Review
- Electroacupuncture protects the intestinal mucosal barrier in diarrhea-predominant Irritable Bowel Syndrome rats by regulating the MCs/Tryptase/PAR-2/MLCK pathway.American journal of translational research · 2024Article
- New insights into irritable bowel syndrome pathophysiological mechanisms: contribution of epigenetics.Journal of gastroenterology · 2023Review
- Knockdown of miR-19a suppresses gastrointestinal dysmotility diarrhea after TBI by regulating VIP expression.Brain and behavior · 2023Article
- The Association between Infant Colic and the Multi-Omic Composition of Human Milk.Biomolecules · 2023Article
- MicroRNA-155-5p inhibition alleviates irritable bowel syndrome by increasing claudin-1 and ZO-1 expression.Annals of translational medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a common chronic functional gastrointestinal disorder. MicroRNAs (miRNAs) have been identified to be involved in different physiological and pathological processes. In this study, the role of miRNA-29a in the potential mechanism underlying the function of the intestinal mucosal barrier in IBS-D was analyzed. Human intestinal mucosal epithelia from patients with IBS-D (diagnosed as meeting the Rome IV criteria) and healthy volunteers were collected. An IBS-D mouse model was established via induction with trinitro-benzene-sulfonic acid (TNBS), and the mice were injected with miRNA-29a inhibitor. Using transmission electron microscopy (TEM), the epithelial ultrastructure of the human intestinal mucosa was examined. Using reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis, the expression level of miRNA-29a was assessed. ELISA was used to analyze the activity of D-lactate (D-LA) and diamine oxidase (DAO). Through immunohistochemistry, RT-qPCR and western blotting, the expression of tight junction protein ZO-1 (ZO-1) and claudin-1 (CLDN1) was examined. In the human intestinal mucosal epithelia from patients with IBS-D, miRNA-29a was upregulated, ZO-1 and CLDN1 were downregulated, and the junctional complex (JC) was faint and discontinuous. In the IBS-D mouse model, treatment with miRNA-29a inhibitor downregulated D-LA and DAO activity, and increased the expression of ZO-1 and CLDN1 in the intestinal mucosal epithelium. In conclusion, the present study revealed that miRNA-29a is involved in the pathogenesis of IBS-D, probably by downregulating ZO-1 and CLDN1 expression, suggesting that miRNA-29a is likely to be an important regulator of intestinal barrier function and could be a possible therapeutic target for IBS-D.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.